Blood-based miRNAs as noninvasive diagnostic and surrogative biomarkers in colorectal cancer

Expert Review of Molecular Diagnostics

Volumn 13, Issue 2, 2013, Pages 141-145

  Gall, Tamara Mh ^a   Frampton, Adam E ^a   Krell, Jonathan ^a   Castellano, Leandro ^a   Stebbing, Justin ^b   Jiao, Long R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

biomarker; colorectal cancer; diagnostic; miR 21; miRNA

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 141; MICRORNA 17; MICRORNA 17 3P; MICRORNA 19A; MICRORNA 21; MICRORNA 22; MICRORNA 221; MICRORNA 224; MICRORNA 29A; MICRORNA 34A; MICRORNA 34B; MICRORNA 601; MICRORNA 7; MICRORNA 760; MICRORNA 92A; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER SURVIVAL; COLORECTAL CANCER; DOWN REGULATION; ENTERITIS; HUMAN; IN VITRO STUDY; NON INVASIVE MEASUREMENT; OCCULT BLOOD; PROTEIN EXPRESSION; PROTEIN PROCESSING; SENSITIVITY AND SPECIFICITY; UPREGULATION;

EID: 84874824723     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.13.2     Document Type: Article

References (26)

1. Kanaan Z, Rai SN, Eichenberger MR et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann. Surg. 256(3), 544-551 (2012).
2. Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J. Cell. Mol. Med. 13(1), 39-53 (2009).
3. Aslam MI, Taylor K, Pringle JH, Jameson JS. MicroRNAs are novel biomarkers of colorectal cancer. Br. J. Surg. 96(7), 702-710 (2009).
4. Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet 365(9454), 153-165 (2005).
5. Slaby O, Svoboda M, Fabian P et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72(5-6), 397-402 (2007).
6. Xu XM, Qian JC, Deng ZL et al. Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer. Oncol. Lett. 4(2), 339-345 (2012).
7. Schee K, Boye K, Abrahamsen TW, Fodstad O, Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 12, 505 (2012).
8. Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299(4), 425-436 (2008).
9. Motoyama K, Inoue H, Takatsuno Y et al. Over-and under-expressed microRNAs in human colorectal cancer. Int. J. Oncol. 34(4), 1069-1075 (2009).
10. Bandrés E, Cubedo E, Agirre X et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol. Cancer 5, 29 (2006).
11. Arndt GM, Dossey L, Cullen LM et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 9, 374 (2009).
12. Olaru AV, Selaru FM, Mori Y et al. Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation. Inflamm. Bowel Dis. 17(1), 221-231 (2011).
13. Nagel R, le Sage C, Diosdado B et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 68(14), 5795-5802 (2008).
14. Zhou W, Li X, Liu F et al. MiR-135a promotes growth and invasion of colorectal cancer via metastasis suppressor 1 in vitro. Acta Biochim. Biophys. Sin. (Shanghai) 44(10), 838-846 (2012).
15. Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J. Cancer Res. Clin. Oncol. 138(10), 1659-1666 (2012).
16. Cheng H, Zhang L, Cogdell DE et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 6(3), e17745 (2011).
17. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 127(1), 118-126 (2010).
18. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105(30), 10513-10518 (2008).
19. Cookson VJ, Bentley MA, Hogan BV et al. Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell. Oncol. (Dordr.) 35(4), 301-308 (2012).
20. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 14(5), 844-852 (2008).
21. Bartley AN, Yao H, Barkoh BA et al. Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellitestable colorectal cancer. Clin. Cancer Res. 17(23), 7283-7293 (2011).
22. Paraskevi A, Theodoropoulos G, Papaconstantinou I, Mantzaris G, Nikiteas N, Gazouli M. Circulating MicroRNA in inflammatory bowel disease. J. Crohns Colitis 6(9), 900-904 (2012).
23. Ng EK, Chong WW, Jin H et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58(10), 1375-1381 (2009).
24. Wang Q, Huang Z, Ni S et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One 7(9), e44398 (2012).
25. Nugent M, Miller N, Kerin MJ. Circulating miR-34a levels are reduced in colorectal cancer. J. Surg. Oncol. 106(8), 947-952 (2012).
26. Pu XX, Huang GL, Guo HQ et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J. Gastroenterol. Hepatol. 25(10), 1674-1680 (2010).